Name: INDV Income Statement - Indivior Pharmaceuticals Revenue & EPS | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Revenue, Cost of Revenue, Gross Profit, Operating Expenses, Operating Income, Net Income, EPS Basic, EPS Diluted

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

INDV - Indivior Pharmaceuticals, Inc.

USD | NASDAQ | Healthcare

INDV Income Statement - Indivior Pharmaceuticals Revenue & EPS | Ledgeburg

(in millions of USD, except per-share data)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24
Revenues
Revenues	317.0	357.0	314.0	302.0	266.0	298.0	307.0	299.0	284.0
Cost of Revenue	40.0	67.0	83.0	52.0	44.0	48.0	66.0	79.0	38.0
Gross Profit	277.0	290.0	231.0	250.0	222.0	250.0	241.0	220.0	246.0
Operating Expenses
Research & Development	-	-	-	-	-	-	-	-	-
Selling General & Administrative	124.0	188.0	155.0	158.0
Operating Income
Operating Income	137.0	81.0	43.0	72.0	66.0	46.0	35.0	(118.0)	75.0
Non-Operating
Interest Income	3.0	6.0	6.0	6.0	4.0	5.0	5.0	6.0	7.0
Interest Expense	7.0	6.0	12.0	15.0	12.0
Tax & Net
Income Tax Expense	26.0	(21.0)	(5.0)	44.0	11.0	17.0	8.0	(23.0)	11.0
Net Income From Continuing Ops	89.0	103.0	42.0	18.0
Per Share
EPS Basic	0.71	-	0.34	0.15	0.38	-	0.16	(0.72)	0.45
EPS Diluted	0.69	-	0.33	0.14	0.38
Supplementary Data
EBITDA	139.0	-	-	-	69.0	-	-	-	80.0
EBIT	137.0	81.0	43.0	72.0	66.0	46.0

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD, except per-share data)	TTM	FY2025	FY2024	FY2023	FY2022
Revenues
Revenues	1,290.0	1,239.0	1,188.0	1,093.0	901.0
Cost of Revenue	242.0	246.0	231.0	174.0	151.0
Gross Profit	1,048.0	993.0	957.0	919.0	750.0
Operating Expenses
Research & Development	-	-	-	-	-
Selling General & Administrative	625.0	634.0	612.0	565.0	469.0
Selling & Marketing	-
Operating Income
Operating Income	333.0	262.0	38.0	(152.0)	(81.0)
Non-Operating
Interest Income	21.0	22.0	23.0	43.0	19.0
Interest Expense	40.0	45.0	41.0	35.0	27.0
Income From Equity Investments	-
Tax & Net
Income Tax Expense	44.0	29.0	13.0	(19.0)	(44.0)
Net Income From Continuing Ops	252.0	210.0	7.0	(126.0)	(44.0)
Net Income From Discontinued Ops	-
Per Share
EPS Basic	2.03	1.68	0.05	(0.92)	(0.32)
EPS Diluted	1.95	1.64	0.05	(0.92)	(0.32)
Shares Basic	124.0	125.0
Supplementary Data
EBITDA	-	272.0	54.0	(137.0)	(65.0)
EBIT	333.0	262.0	38.0	(152.0)	(81.0)

Source: SEC EDGAR company filings. Figures as reported (US GAAP)